Literature DB >> 11709340

Action of deferoxamine against Pneumocystis carinii.

A B Clarkson1, D Turkel-Parrella, J H Williams, L C Chen, T Gordon, S Merali.   

Abstract

We found earlier that deferoxamine (DFO), a drug used for treatment of iron overload, is active against a rat model of Pneumocystis carinii pneumonia (PCP). We had assumed a mode of action by deprivation of nutritional iron; however, data here show that DFO penetrates P. carinii, causing irreversible damage, thus indicating a different mode of action. Penetration was demonstrated by showing DFO uptake by high-pressure liquid chromatography analysis. By using calcein-AM as an indicator, exposure to DFO was shown to cause a reduction in P. carinii cytoplasmic free iron. Exposure to >or=100 microM DFO for >or=8 h in vitro caused growth to cease and cell numbers to decline over several days. This direct and irreversible damage to P. carinii led to the prediction that infrequent delivery of DFO to the lungs via an aerosol would be an effective treatment in the animal model of PCP. This prediction was confirmed by demonstrating that a once-a-week aerosol treatment of rats was 100% effective both as a prophylactic and as a curative treatment in a rat model of PCP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709340      PMCID: PMC90869          DOI: 10.1128/AAC.45.12.3560-3565.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Lack of a role for iron in the Lyme disease pathogen.

Authors:  J E Posey; F C Gherardini
Journal:  Science       Date:  2000-06-02       Impact factor: 47.728

2.  Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii.

Authors:  S Merali; M Saric; K Chin; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung.

Authors:  A R O'Brien-Ladner; S R Nelson; W J Murphy; B M Blumer; L J Wesselius
Journal:  Am J Respir Cell Mol Biol       Date:  2000-07       Impact factor: 6.914

4.  Plasma lactoferrin levels are decreased in end-stage AIDS patients.

Authors:  B W van der Strate; M C Harmsen; T H The; H G Sprenger; H de Vries; M C Eikelboom; M E Kuipers; D K Meijer; P J Swart
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

5.  Antiviral and immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection.

Authors:  T Martelius; M Scholz; L Krogerus; K Höckerstedt; R Loginov; C Bruggeman; J Cinatl; H W Doerr; I Lautenschlager
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

6.  Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.

Authors:  P Lee; N Mohammed; L Marshall; R D Abeysinghe; R C Hider; J B Porter; S Singh
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

7.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Impairment of circulating lactoferrin in HIV-1 infection.

Authors:  M C Defer; B Dugas; O Picard; C Damais
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1995-05       Impact factor: 1.770

10.  Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.

Authors:  S Merali; K Chin; R W Grady; L Weissberger; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  2 in total

1.  Extracellular calcium and magnesium, but not iron, are needed for optimal growth of Blastomyces dermatitidis yeast form cells in vitro.

Authors:  Steven S Giles; Charles J Czuprynski
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

2.  Examination of an inducible expression system for limiting iron availability during Chlamydia trachomatis infection.

Authors:  Brian D Dill; Jane E Raulston
Journal:  Microbes Infect       Date:  2007-04-07       Impact factor: 2.700

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.